Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis
Authors: Kwonjune J. Seung, Palwasha Khan, Molly F. Franke, Saman Ahmed, Stalbek Aiylchiev, Manzur Alam, Fauziah Asnely Putri, Mathieu Bastard, Wisny Docteur, Gary Gottlieb, Catherine Hewison, Shirajul Islam, Naira Khachatryan, Tinatin Kotrikadze, Uzma Khan, Andargachew Kumsa, Leonid Lecca, Yoseph Melaku Tassew, Nara Melikyan, Ye Yint Naing, Lawrence Oyewusi, Michael Rich, Stephen Wanjala, Askar Yedilbayev, Helena Huerga, and Carole D. Mitnick; for the endTB Study Group
Abstract
Delamanid should be effective against highly resistant strains of Mycobacteriumtuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Access to the full article - DOI: 10.1093/cid/ciz1084
Resource type
